Ambroxol, long used for coughs in Europe, stabilized symptoms and brain-damage markers in Parkinson’s dementia patients over ...

A safe and affordable treatment to slow the advancement of Parkinson's dementia has emerged – in the form of a commonly ...

Ambroxol is commonly used as an expectorant in cough syrup, helping thin out mucus so people with respiratory illnesses can ...

Ambroxol chaperones GCase; in a previous study of people with Parkinson's disease, the drug led to increased GCase levels. It ...

Ambroxol – a common cough medicine in Europe – may prevent the progression of dementia in patients with Parkinson's disease, a new trial suggests.

Researchers at Lawson Research Institute (Lawson), the research arm of St. Joseph's Health Care London, are investigating ...

A COMMON cough medicine could help protect against dementia. A study found that it prevented people with Parkinson’s develop ...

A common cough syrup, Ambroxol, has shown potential in slowing the progression of Parkinson's dementia in a recent clinical trial.

A 12-month study found that Ambroxol helped stabilised psychiatric symptoms and protected against brain damage in genetically ...

A clinical trial has revealed that Ambroxol, a common cough medicine in Europe, may help slow cognitive decline in people with Parkinson’s disease dementia.

A commonly sold cough syrup in Europe could potentially slow down progression of dementia in patients with Parkinson’s ...

Ambroxol supports a key enzyme called glucocerebrosidase (GCase), which is produced by the GBA1 gene. In people with Parkinson's disease, GCase levels are often low.